An interventional study of cefuroxime and Saline placebo in Cataract and Endophthalmitis, sponsored by Presbyterian Church East Africa Kikuyu Hospital. Completed at 1 site in Kenya. Open to participants aged 6 Months to 15 Years. Per ClinicalTrials.gov, last updated 2008-08-08.
Sponsored by Presbyterian Church East Africa Kikuyu Hospital · Not applicable, Interventional, and Treatment
The study investigates whether placing an antibiotic inside the eye at the end of cataract surgery in children will reduce the amount of fibrin formation (fibrin formation can block the pupil and reduce vision). We hypothesize that the fibrin is caused by a low-level infection and could be prevented by the antibiotic.
The study investigates whether using an antibiotic (cefuroxime) in the anterior chamber of the eye at the end of surgery for cataract in children will reduce the amount of fibrin formation.
55 studies on the registry are indexed under Endophthalmitis; 8 are open to participants now.
This study's enrollment of 45 is below the median of 113 across 32 interventional studies indexed under Endophthalmitis.
Browse Endophthalmitis studies →This is the only study on the registry with Presbyterian Church East Africa Kikuyu Hospital as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: cefuroxime
Saline placebo
Drug: Saline placebo
intracameral cefuroxime 0.1 ml
Also known as: Zinacef
0.1 ml of Ringers lactate
Also known as: Saline
Fibrin formation in anterior chamber
Time frame: 4th postoperative day
This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.